Vitamin E-based nanoparticle hydrogel turns cold breast tumors hot in mice
A vitamin E-derived lipid nanoparticle hydrogel delivering IL-12 mRNA and an IDO1 inhibitor curbed triple-negative breast cancer growth and recurrence in mice.
Résumé
Triple-negative breast cancer is often an immune 'cold' tumor that resists immunotherapy. Researchers built a vitamin E-based ionizable lipid to carry IL-12 mRNA plus the IDO1 inhibitor NLG919 in lipid nanoparticles, then embedded them in an injectable F127-diacrylate hydrogel that gels with body heat and can be cured with light after surgery. In 4T1 mouse models, the gel stayed in the tumor for about 12 days, boosted dendritic cell activation, reduced regulatory T cells and suppressive myeloid cells, shifted macrophages toward an anti-tumor M1 state, and increased activated T cells. It slowed tumor growth, extended survival, and delayed postoperative recurrence, without the liver enzyme elevations seen with conventional IL-12 LNPs. Findings are preclinical and mouse-only.
Résumé détaillé
Triple-negative breast cancer (TNBC) is aggressive and often 'immune cold,' meaning few effective immune cells infiltrate the tumor and suppressive pathways such as IDO1 dampen responses. mRNA lipid nanoparticles (LNPs) can deliver immune-stimulating cytokines, but standard formulations are inert carriers, are cleared quickly, and can cause systemic toxicity when IL-12 leaks out of the tumor. This study asked whether a lipid with built-in bioactivity, combined with a local depot, could do better.
The team synthesized a vitamin E (α-tocopherol)-based ionizable lipid (VEBIL), screened three variants, and selected VEBIL3N for its uniform size, high mRNA encapsulation, and endosomal escape. The LNPs were co-loaded with IL-12 mRNA and the IDO1 inhibitor NLG919 (N@VEBLNP) and embedded in 20 wt% diacrylate-modified Pluronic F127 hydrogel (NVF Gel). This gel solidifies near body temperature for intratumoral injection and can be photocrosslinked with 405 nm light to hold in a surgical cavity. Testing included in vitro dendritic cell and macrophage assays, bioluminescence tracking, orthotopic 4T1 tumor treatment, a resection-recurrence model, flow cytometry, and tumor transcriptomics.
In vitro, NVF Gel increased antigen cross-presentation and maturation markers (CD80, CD86, MHC II) in dendritic cells compared with a Dlin-MC3-DMA control gel, and repolarized M2-like macrophages: about 3.5-fold more CD80+ cells, less CD206, greater phagocytosis, more TNF-α, IL-6 and IL-12p70 (over 2.1-fold versus conventional LNPs), and less IL-10 and TGF-β. In mice, the gel sustained transgene expression up to 48 h, degraded over roughly 12 days, and stayed confined to the tumor. A single injection produced the strongest tumor suppression and survival benefit among groups. Tumors showed about 3.8-fold more cDC1s, lower IDO1 and kynurenine/tryptophan ratio, fewer Tregs and MDSCs, more M1-like macrophages, and more activated CD69+ CD4 and CD8 T cells. Transcriptomics showed upregulated IFN-γ, CXCL9/10, and granzyme B pathways. After surgery, the gel delayed recurrence and extended survival, with immune-memory analyses reported.
Implications: a bioactive lipid plus a dual-mode hydrogel could make local mRNA immunotherapy more durable and safer, and may address both unresectable tumors and post-surgical relapse. Notably, conventional IL-12 LNPs raised ALT and AST, whereas the VEBIL formulations did not.
Caveats: all data come from a single murine TNBC model (4T1) with small groups (n=3-5). The vitamin E contribution was inferred from comparison with a different lipid, not isolated, and no human or long-term safety data exist.
Principales conclusions
- VEBIL-based LNPs achieved efficient mRNA delivery and endosomal escape, with EGFP expression comparable to Lipofectamine 3K in 4T1 cells.
- NVF Gel gelled at about 30-33 °C or under 405 nm light, stayed in tumors, and degraded over roughly 12 days.
- Treated tumors had about 3.8-fold more cDC1s, fewer Tregs and MDSCs, lower IDO1, and more activated CD4/CD8 T cells.
- A single intratumoral NVF Gel dose gave the strongest tumor suppression and survival benefit versus free nanoparticles and conventional LNPs.
- NVF Gel delayed postoperative recurrence and avoided the ALT/AST elevations seen with conventional IL-12 mRNA LNPs.
Méthodologie
Preclinical study combining lipid synthesis and LNP optimization, hydrogel characterization (rheology, SEM, release), in vitro dendritic cell and macrophage co-culture assays, and in vivo 4T1 orthotopic and resection-recurrence mouse models with imaging, flow cytometry, immunofluorescence, HPLC, and transcriptomics. Group sizes were small (n=3-5).
Limites de l'étude
Evidence is limited to one murine breast cancer model with small groups, and the immune-memory and full survival data were partly truncated in the provided text. The specific contribution of vitamin E versus other lipid features was not isolated, and long-term safety, immunogenicity, and efficacy in metastatic or human tumors remain untested.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :